Location:2011 Annual Report
1a. Objectives (from AD-416)
1. To develop reagents for the sensitive detection of BoNTs in ELISA or ALISSA assay formats. 2. To optimize techniques for the recovery and detection of toxin in animal tissues and sera. 3. To determine the pharmacokinetics of botulinum neurotoxins in oral and parenteral mouse models of intoxication.
1b. Approach (from AD-416)
Monoclonal antibodies directed against botulinum neurotoxins (BoNTs) serotypes B, E and F will be produced and used in sensitive in vitro assays to detect toxin in animal sera and tissues. Animals will be intoxicated and the half life and tissue distribution of the toxins determined. Documents Trust with UC Irvine. Log 36536. Formerly 5325-42000-043-04R (4/11)
3. Progress Report
The research included collaborative development of assay technologies for detection of botulinum neurotoxins (BoNTs) in food and sera. Monoclonal antibodies against BoNT/A and BoNT/B were optimized for the detection of toxin in sera using a multiwell plate-based electrochemiluminescence (ECL) assay system. Pharmacokinetics of BoNTs were studied in sera using the ECL assay system. Collaborators provided humanized therapeutic antibodies for testing of toxin neutralization and expertise in new assay technology for the detection and visualization of toxin in organs. Collaboration is facilitated by annual meetings of the Pacific Southwest Regional Center of Excellence, e-mail, and ad hoc meetings with collaborating laboratory personnel. Manuscripts have been prepared and yearly renewal reports are submitted to the granting agency (DHHS-PHS-NIH National Institute of Allergy and Infectious Diseases).